SAGE Therapeutics Inc Sage FutureCast: An R&D and Portfolio Review Transcript

The following is excerpted from the question-and-answer section of the transcript.

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : First on zuranolone, there's a lot of different approaches you're looking at. Is it most likely the first indication would be simultaneous with other antidepressants and then followed by other indications for use as monotherapy? Is that the likely approach that we'll see?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Okay. And then if you use zuranolone together with other antidepressants, any concerns with drug-drug interactions, as you're exploring the higher 50-milligram dose in greater detail?

Question: Gary Jay Nachman - BMO Capital Markets Equity Research - Analyst : Okay. And then just lastly on brexanolone for the COVID patients, would they take that with anything else potentially? Or is the study just looking at monotherapy? And what's the timeline for getting that data?

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : I have a couple, both on zuranolone. We appear to be moving from chronic to episodic treatment of MDD as we see these developments in relatively rapid-acting treatments. But at what point should we start thinking about episodic treatments potentially morphing into prophylactic treatments for MDD? And is there any quantification you can provide on how long durability should be for an MDD treatment to be considered a preventive? And then I have a follow-up.

Question: Sumant Satchidanand Kulkarni - Canaccord Genuity Corp., Research Division - Analyst : Got it. And the second question is sort of corollary to that. In your clinical development programs so far, what have you found out and how easy or difficult it would to convince patients that they may not need to be on a chronic therapy to stay better?